Samjin Pharm (005500)

Currency in KRW
22,100
-2,600(-10.53%)
Delayed Data·
Unusual trading volume
005500 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21,75023,850
52 wk Range
16,99025,900
Key Statistics
Bid/Ask
21,900.00 / 22,000.00
Prev. Close
24,700
Open
23,550
Day's Range
21,750-23,850
52 wk Range
16,990-25,900
Volume
559.78K
Average Volume (3m)
138.79K
1-Year Change
27.5245%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
005500 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24,000
Upside
+8.60%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24,000
(+8.60% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
May 19, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1,727.82%
Dividend Yield
4.01%
Industry Median 0.99%
Annualized payout
800.00
Paid annually
5-Years Growth
-
Growth Streak

005500 Income Statement

Compare 005500 to Peers and Sector

Metrics to compare
005500
Peers
Sector
Relationship
P/E Ratio
0.0x5.8x−0.5x
PEG Ratio
0.000.010.00
Price/Book
0.0x1.0x2.6x
Price / LTM Sales
0.0x0.7x3.1x
Upside (Analyst Target)
0.0%51.6%55.1%
Fair Value Upside
Unlock10.2%7.2%Unlock

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer’s and Parkinson’s disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.

Employees
586

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
144.63K1.18%2.88B
Other Institutional Investors
2.50M20.38%49.81B
Public Companies & Retail Investors
9.62M78.44%191.72B
Total
12.26M100.00%244.42B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Hana Pharm Co., Ltd.9.34%1,145,19822,835,248
AriBio Co., Ltd.9.06%1,111,11122,155,553

People Also Watch

100,800
272210
-3.17%
8,120
001740
-0.98%
8,110
002900
-0.49%
9,900
003720
-4.72%
950,000
009150
-3.75%

FAQ

What Is the Samjin Pharm (005500) Stock Price Today?

The Samjin Pharm stock price today is 22,100 KRW.

What Stock Exchange Does Samjin Pharm Trade On?

Samjin Pharm is listed and trades on the Seoul Stock Exchange.

What Is the Stock Symbol for Samjin Pharm?

The stock symbol for Samjin Pharm is "005500."

Does Samjin Pharm Pay Dividends? What’s The Current Dividend Yield?

The Samjin Pharm dividend yield is 3.24%.

What Is the Samjin Pharm Market Cap?

As of today, Samjin Pharm market cap is 302.77B KRW.

What Is Samjin Pharm's Earnings Per Share (TTM)?

The Samjin Pharm EPS (TTM) is 1,728.

When Is the Next Samjin Pharm Earnings Date?

Samjin Pharm will release its next earnings report on May 19, 2026.

From a Technical Analysis Perspective, Is 005500 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Samjin Pharm Stock Split?

Samjin Pharm has split 6 times.

How Many Employees Does Samjin Pharm Have?

Samjin Pharm has 586 employees.

What is the current trading status of Samjin Pharm (005500)?

As of May 20, 2026, Samjin Pharm (005500) is trading at a price of 22,100 KRW, with a previous close of 24,700 KRW. The stock has fluctuated within a day range of 21,750 KRW to 23,850 KRW, while its 52-week range spans from 16,990 KRW to 25,900 KRW.

What Is Samjin Pharm (005500) Price Target According to Analysts?

The average 12-month price target for Samjin Pharm is 24,000 KRW, with a high estimate of 24000 KRW and a low estimate of 24000 KRW. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +8.60% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.